Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT – 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase I clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and LT2003, which is in pre-clinical stage for the treatment of oncology. In addition, the company engages in the investment, consulting, service, and transfer of techniques activities. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is headquartered in Taipei, Taiwan.
Metrics to compare | 6535 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6535PeersSector | |
---|---|---|---|---|
P/E Ratio | −59.2x | −12.9x | −0.5x | |
PEG Ratio | −3.30 | 0.09 | 0.00 | |
Price/Book | 13.5x | 1.9x | 2.6x | |
Price / LTM Sales | 561.6x | 4.8x | 3.2x | |
Upside (Analyst Target) | 58.6% | 0.0% | 44.6% | |
Fair Value Upside | Unlock | 0.8% | 6.5% | Unlock |